EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

Search

Sanofi SA

Gesloten

SectorGezondheidszorg

99.62 -0.56

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

99.51

Max

101.9

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.3B

499M

Verkoop

-6.5B

7.6B

K/W

Sectorgemiddelde

23.216

63.778

EPS

1.31

Dividendrendement

3.79

Winstmarge

6.539

Werknemers

82,878

EBITDA

-3.7B

563M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+15.12% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.79%

2.39%

Volgende Winsten

24 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-6B

125B

Vorige openingsprijs

100.18

Vorige sluitingsprijs

99.62

Nieuwssentiment

By Acuity

33%

67%

106 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Sanofi SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mrt 2025, 06:43 UTC

Acquisities, Fusies, Overnames

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5 feb 2025, 13:41 UTC

Winsten

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5 feb 2025, 07:10 UTC

Winsten

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5 feb 2025, 06:39 UTC

Winsten

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

2 apr 2025, 13:44 UTC

Marktinformatie

Santander Push Into Canada on the Cards -- Market Talk

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mrt 2025, 06:19 UTC

Marktinformatie
Winsten

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mrt 2025, 10:08 UTC

Marktinformatie

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mrt 2025, 09:00 UTC

Top Nieuws

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mrt 2025, 06:05 UTC

Acquisities, Fusies, Overnames

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mrt 2025, 06:05 UTC

Acquisities, Fusies, Overnames

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mrt 2025, 06:04 UTC

Acquisities, Fusies, Overnames

Sanofi to Pay $600M Upfront

20 mrt 2025, 06:02 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mrt 2025, 06:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mrt 2025, 09:33 UTC

Populaire aandelen

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mrt 2025, 23:00 UTC

Top Nieuws

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mrt 2025, 09:50 UTC

Winsten

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mrt 2025, 09:49 UTC

Winsten

Santander Increased 2024 Cash Payments by 19%

24 feb 2025, 08:56 UTC

Marktinformatie
Winsten

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 feb 2025, 08:30 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19 feb 2025, 06:35 UTC

Acquisities, Fusies, Overnames

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 feb 2025, 06:34 UTC

Acquisities, Fusies, Overnames

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 feb 2025, 06:34 UTC

Acquisities, Fusies, Overnames

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 feb 2025, 06:32 UTC

Acquisities, Fusies, Overnames

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 feb 2025, 06:31 UTC

Acquisities, Fusies, Overnames

Sanofi, CD&R Sign Opella Share Purchase Agreement

14 feb 2025, 10:55 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5 feb 2025, 07:48 UTC

Marktinformatie
Winsten

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

Peer Vergelijking

Prijswijziging

Sanofi SA Prognose

Koersdoel

By TipRanks

15.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 115.584 EUR  15.12%

Hoogste 125 EUR

Laagste 92 EUR

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technische score

By Trading Central

100.38 / 101.44Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

106 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.